Patent Watch: Cryogenic Cannabinoid Nanoparticles Target Improved Beverage Delivery
The application claims a process for producing cannabinoid nanoparticles under cryogenic conditions and incorporating them into beverage compositions. Cannabinoids serve as the active ingredients, while nanoparticle engineering and the beverage matrix function as the delivery system, with specific excipients not established in the published disclosure.
Clinical Perspective & Therapeutic Significance
Smaller cannabinoid particles may improve aqueous dispersion, dose uniformity, and potentially the onset or consistency of oral absorption compared with conventional oil-based beverages. These potential advantages require pharmacokinetic, stability, toxicology, and human clinical studies, particularly because a patent filing does not demonstrate efficacy or safety.
Intellectual Property & Market Landscape
The application is listed as independent and unassigned, suggesting an early-stage asset without a disclosed corporate commercialization partner. Its positioning differs from standard cannabis beverages that commonly rely on emulsions, encapsulation, or surfactant-based water-compatible systems, although manufacturing cost and scale may affect competitiveness.
Cryogenic nanoparticle production is a technically interesting approach to a persistent cannabinoid beverage problem, but its practical value will depend on reproducible dosing, shelf stability, safety, and demonstrated absorption in humans.
Frequently Asked Questions
Could cryogenic cannabinoid nanoparticles make a cannabis beverage work faster?
Does this patent mean the beverage has completed clinical trials?
When could beverages using this process become available?
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
